Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Deferred Tax (2016 - 2018)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Deferred Tax over the past 4 years, most recently at $17.5 million for Q2 2018.

  • Quarterly results put Long-Term Deferred Tax at $17.5 million for Q2 2018, down 28.87% from a year ago — trailing twelve months through May 2018 was $17.5 million (down 28.87% YoY), and the annual figure for FY2018 was $17.5 million, down 28.87%.
  • Long-Term Deferred Tax for Q2 2018 was $17.5 million at Lifecore Biomedical, Inc. \De\, down from $24.6 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for LFCR hit a ceiling of $32.2 million in Q2 2015 and a floor of $17.5 million in Q2 2018.
  • Median Long-Term Deferred Tax over the past 4 years was $23.5 million (2016), compared with a mean of $24.2 million.
  • Biggest five-year swings in Long-Term Deferred Tax: tumbled 30.37% in 2016 and later grew 9.53% in 2017.
  • Lifecore Biomedical, Inc. \De\'s Long-Term Deferred Tax stood at $32.2 million in 2015, then tumbled by 30.37% to $22.4 million in 2016, then rose by 9.53% to $24.6 million in 2017, then dropped by 28.87% to $17.5 million in 2018.
  • The last three reported values for Long-Term Deferred Tax were $17.5 million (Q2 2018), $24.6 million (Q2 2017), and $22.4 million (Q2 2016) per Business Quant data.